ImmuPharma (LON:IMM) Stock Price Up 25.4% - Still a Buy?

Key Points

• ImmuPharma's stock price surged 25.4% during trading, reaching a high of GBX 11.75 ($0.16), with trading volume increasing by 30% compared to its average.
• The company reported a negative earnings per share (EPS) of GBX (0.38) for the last quarter and is projected to post approximately -339 earnings per share for the current year.
• ImmuPharma is a biopharmaceutical firm focused on peptide-based therapeutics for autoimmune diseases, with its leading program targeting Lupus through the drug Lupuzor™.

Shares of ImmuPharma plc (LON:IMM - Get Free Report) shot up 25.4% during mid-day trading on Tuesday . The company traded as high as GBX 11.75 ($0.16) and last traded at GBX 11.02 ($0.15). 11,169,137 shares traded hands during trading, an increase of 30% from the average session volume of 8,583,759 shares. The stock had previously closed at GBX 8.79 ($0.12).

ImmuPharma Price Performance

The company has a market cap of £54.22 million, a PE ratio of -1,219.10 and a beta of 1.53. The company has a 50-day moving average price of GBX 5.30 and a two-hundred day moving average price of GBX 3.58.

ImmuPharma (LON:IMM - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. On average, equities research analysts anticipate that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.